Breast Cancer Research and Treatment

, Volume 172, Issue 1, pp 239–240 | Cite as

Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy

  • Mattia Rediti
  • Carlo MessinaEmail author
Letter to the Editor


Compliance with ethical standards

Conflict of interest

All authors declare no conflicts of interest.

Ethical approval

This study does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

It was unnecessary given this letter does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Poggio F, Bruzzone M, Ceppi M et al. (2018) Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. CrossRefPubMedGoogle Scholar
  2. 2.
    Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767CrossRefGoogle Scholar
  3. 3.
    Bareche Y, Venet D, Ignatiadis M et al. (2018) Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 29(4):895–902CrossRefGoogle Scholar
  4. 4.
    Telli ML, Timms KM, Reid J et al. (2016) Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22(15):3764–73CrossRefGoogle Scholar
  5. 5.
    Telli ML, Metzger O, Timms KM et al. (2018) Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin ± veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. J Clin Oncol 36:519 (suppl; abstr 519)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Medical Oncology UnitAzienda Ospedaliero-Universitaria CareggiFlorenceItaly
  2. 2.Academic Unit of Medical Oncology, Department of Internal Medicine, School of Medicine, Policlinico Hospital San Martino-ISTUniversity of GenoaGenoaItaly

Personalised recommendations